Literature DB >> 10864876

Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 in vitro.

R Anderson1, S S Visser, G Ramafi, A J Theron.   

Abstract

We have investigated the effects of the adenosine A(2A) receptor agonist CGS 21680 (0.01 - 1 microM) on reactive oxidant production by, and elastase release from FMLP-activated human neutrophils, as well as on cytosolic Ca(2+) fluxes and intracellular concentrations of cyclic AMP. Oxidant production, elastase release and cyclic AMP were assayed using lucigenin-enhanced chemiluminescence, colourimetric and radioimmunoassay procedures respectively, while cytosolic Ca(2+) fluxes were measured by fura-2 spectrofluorimetry in combination with radiometric procedures which distinguish between net efflux and influx of the cation. Treatment of neutrophils with CGS 21680 did not affect the FMLP-activated release of Ca(2+) from intracellular stores, but resulted in dose-related acceleration of the rate of decline in fura-2 fluorescence, as well as decreases in both efflux and store-operated influx of Ca(2+), compatible with enhancement of resequestration of the cation by the endo-membrane Ca(2+)-ATPase. These effects on neutrophil Ca(2+) handling were associated with increased intracellular cyclic AMP and with inhibition of oxidant production and release of elastase. In contrast, treatment of neutrophils with the selective A(2A) receptor antagonist, ZM 241385 (2.5 microM), prevented the transient increase in cyclic AMP in FMLP-activated neutrophils which was associated with delayed sequestration of incoming Ca(2+) during store-operated influx. The CGS 21680-mediated reduction of Ca(2+) efflux from FMLP-activated neutrophils was also antagonized by pretreatment of the cells with ZM 241385 (2.5 microM), as well as by thapsigargin (1 microM), an inhibitor of the endo-membrane Ca(2+)-ATPase. ZM 241385 also neutralized the cyclic AMP-elevating and anti-inflammatory interactions of CGS 21680 with neutrophils. We conclude that A(2A) receptors regulate the pro-inflammatory activities of human neutrophils by promoting cyclic AMP-dependent sequestration of cytosolic Ca(2+).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864876      PMCID: PMC1572119          DOI: 10.1038/sj.bjp.0703344

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

Review 1.  The calcium pump of the surface membrane and of the sarcoplasmic reticulum.

Authors:  H J Schatzmann
Journal:  Annu Rev Physiol       Date:  1989       Impact factor: 19.318

2.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

3.  Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils.

Authors:  P Wang; P Wu; K M Ohleth; R W Egan; M M Billah
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

4.  Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils.

Authors:  B N Cronstein; E D Rosenstein; S B Kramer; G Weissmann; R Hirschhorn
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

Review 5.  Calciosome, a sarcoplasmic reticulum-like organelle involved in intracellular Ca2+-handling by non-muscle cells: studies in human neutrophils and HL-60 cells.

Authors:  K H Krause; D Pittet; P Volpe; T Pozzan; J Meldolesi; D P Lew
Journal:  Cell Calcium       Date:  1989-07       Impact factor: 6.817

6.  Lucigenin-dependent chemiluminescence as a new assay for NAD(P)H-oxidase activity in particulate fractions of human polymorphonuclear leukocytes.

Authors:  I Minkenberg; E Ferber
Journal:  J Immunol Methods       Date:  1984-06-08       Impact factor: 2.303

7.  In vitro stimulation of neutrophil motility by levamisole: maintenance of cgmp levels in chemotactically stimulated levamisole-treated neutrophils.

Authors:  R Anderson; A Glover; H J Koornhof; A R Rabson
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

8.  Ca2+ homeostasis in permeabilized human neutrophils. Characterization of Ca2+-sequestering pools and the action of inositol 1,4,5-triphosphate.

Authors:  M Prentki; C B Wollheim; P D Lew
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

9.  Adenosine triphosphate-dependent calcium pump in the plasma membrane of guinea pig and human neutrophils.

Authors:  H Lagast; P D Lew; F A Waldvogel
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

10.  Quantitative analysis of the cytosolic free calcium dependency of exocytosis from three subcellular compartments in intact human neutrophils.

Authors:  P D Lew; A Monod; F A Waldvogel; B Dewald; M Baggiolini; T Pozzan
Journal:  J Cell Biol       Date:  1986-06       Impact factor: 10.539

View more
  13 in total

1.  P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice.

Authors:  Roxane Darbousset; Céline Delierneux; Soraya Mezouar; Alexandre Hego; Christelle Lecut; Isabelle Guillaumat; Markus A Riederer; Richard J Evans; Françoise Dignat-George; Laurence Panicot-Dubois; Cécile Oury; Christophe Dubois
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

Review 2.  Regulation of neutrophil function by adenosine.

Authors:  Kathryn E Barletta; Klaus Ley; Borna Mehrad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

3.  Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils.

Authors:  Dharini van der Hoeven; Elizabeth T Gizewski; John A Auchampach
Journal:  Biochem Pharmacol       Date:  2010-02-10       Impact factor: 5.858

4.  Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium.

Authors:  H C Steel; R Anderson
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 5.  Activation of β2 adrenergic receptor signaling modulates inflammation: a target limiting the progression of kidney diseases.

Authors:  Debra Dorotea; Hunjoo Ha
Journal:  Arch Pharm Res       Date:  2020-11-05       Impact factor: 4.946

6.  Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism.

Authors:  Ronald Anderson; Annette J Theron; Cornelia M Gravett; Helen C Steel; Gregory R Tintinger; Charles Feldman
Journal:  Br J Pharmacol       Date:  2008-12-06       Impact factor: 8.739

7.  Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.

Authors:  Carmelo Carmona-Rivera; Sami S Khaznadar; Kyawt W Shwin; Jorge A Irizarry-Caro; Liam J O'Neil; Yudong Liu; Kenneth A Jacobson; Amanda K Ombrello; Deborah L Stone; Wanxia L Tsai; Daniel L Kastner; Ivona Aksentijevich; Mariana J Kaplan; Peter C Grayson
Journal:  Blood       Date:  2019-04-23       Impact factor: 25.476

Review 8.  Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury.

Authors:  Djo Hasan; Paul Blankman; Gary F Nieman
Journal:  Purinergic Signal       Date:  2017-05-26       Impact factor: 3.765

Review 9.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

Review 10.  Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

Authors:  Annette J Theron; Helen C Steel; Gregory R Tintinger; Charles Feldman; Ronald Anderson
Journal:  Drug Des Devel Ther       Date:  2013-11-22       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.